Insulet initiated a lot-specific voluntary recall of 40,846 boxes (10 Pods per box) of the OmniPod (Pod) Insulin Management System. This field corrective action is due to the possibility that some of the Pods from these lots may have a higher rate of failure than Insulet’s current manufacturing standards. For …
Read More »FDA Approves Synjardy
Empagliflozin/metformin is new combo medication for type 2 diabetes. More information coming in next week’s newsletter.
Read More »New Insulin Now Available
New insulin now available: Humalog® 200 units/mL KwikPen®. See Product of the Week.
Read More »Cheer On Team Novo Nordisk
Tune in to watch Team Novo Nordisk compete at the USA Pro Challenge in Colorado from August 17-23. The race will air on Universal Sports daily and on NBC on Sunday (https://www.usaprocyclingchallenge.com/media-press/tv-coverage) and will stream online for free (https://www.cyclingnews.com/news/watch-the-usa-pro-challenge-live-online-for-free/).
Read More »Medtronic Alerts FDA to Problem With Insulin Pumps
There is an issue with the bolus screen display. The wrong bolus amount may appear on the screen due to an error with the Bolus Wizard. The company is telling patients that blood glucose levels based on a bolus that is more than 12 minutes old should not be used …
Read More »FDA: NSAIDs Drug Safety Communication
Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Drug Safety Communication. FDA Strengthens Warning of Increased Chance of Heart Attack or Stroke. More info here.
Read More »FDA Panel Favors Approval of Alirocumab and Evolocumab for Hypercholesterolemia
FDA Panel Favors Approval of Alirocumab and Evolocumab for Hypercholesterolemia. Two PCSK9 inhibitors have been recommended for approval. The agency will likely follow the advisory committee’s advice when it decides whether to approve the drugs, alirocumab (Praluent) from Sanofi SA and Regeneron Pharmaceuticals Inc., and evolocumab (Repatha) from Amgen Inc., for …
Read More »U.S. FDA Approves Eli Lillys Humalog® 200 units/mL KwikPen®
See the Product of the Week.
Read More »New Bill in Congress to Help Prevent the Diabetes Epidemic
Now if we can get them to pass it, we could reduce cost by billions and improve the quality of life for millions. See this week’s Item #1.
Read More »Intarcia Therapeutics Raises Funds for Pump Development
Intarcia Therapeutics was able to raise an additional $225 million to continue their development and commercialization of an implantable pump that delivers a year’s supply of exenatide. See Product of the Week.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.